Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PureTech Health ( (GB:PRTC) ) has provided an update.
PureTech Health announced its total voting rights and share capital as of June 30, 2025, with 257,927,489 issued ordinary shares and 17,673,040 shares held in treasury, resulting in 240,254,449 voting rights. This information is crucial for shareholders to assess their interests in the company under regulatory guidelines, impacting their decision-making and compliance with disclosure rules.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall stock score reflects a strong financial position and positive corporate developments, tempered by ongoing profitability challenges and bearish technical indicators. The company’s strategic achievements and undervalued P/E ratio are positive, but operational risks and funding concerns for trials remain significant.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to improve the lives of patients with severe diseases. The company has built a comprehensive portfolio through its research and development team and collaborations with scientists, clinicians, and industry leaders. PureTech has developed 29 therapeutics and candidates, with three approved by the U.S. FDA, and continues to advance various programs through its internal efforts and Founded Entities.
Average Trading Volume: 588,910
Technical Sentiment Signal: Sell
Current Market Cap: £303.6M
For an in-depth examination of PRTC stock, go to TipRanks’ Overview page.